Ingram M, Jacques S, Freshwater D B, Techy G B, Shelden C H, Helsper J T
Experimental and Clinical Immunotherapy Laboratory, Huntington Medical Research Institutes, Pasadena, CA 91101.
Arch Surg. 1987 Dec;122(12):1483-6. doi: 10.1001/archsurg.1987.01400240131025.
We present the preliminary results of a phase I trial of adoptive immunotherapy for recurrent or residual malignant glioma. The protocol is based on surgical debulking followed by implantation into the tumor bed of autologous lymphocytes that have been stimulated with phytohemagglutinin-P and then cultured in vitro in the presence of interleukin 2. Fifty-five patients with a mean Karnofsky rating of 64 were treated between February 1985 and March 1987. No significant toxicity was associated with the immunotherapy. Fifty patients had a positive initial response to therapy, nine patients had early recurrence (two to four months after treatment), and 22 patients died. We comment on major differences between the protocol described and other immunotherapy protocols.
我们展示了一项针对复发性或残留性恶性胶质瘤的过继性免疫疗法I期试验的初步结果。该方案基于手术减瘤，随后将经植物血凝素-P刺激并在白细胞介素2存在下体外培养的自体淋巴细胞植入肿瘤床。1985年2月至1987年3月期间，对55名平均卡诺夫斯基评分64的患者进行了治疗。免疫疗法未产生明显毒性。50名患者对治疗有阳性初始反应，9名患者早期复发（治疗后两到四个月），22名患者死亡。我们对所述方案与其他免疫疗法方案之间的主要差异进行了评论。
